Test performance of faecal occult blood testing for the detection of bowel cancer in people with chronic kidney disease (DETECT) protocol

BMC Public Health

Volumn 11, Issue , 2011, Pages

  Wong, Germaine ^a,b,c   Howard, Kirsten ^a   Chapman, Jeremy R ^b   Tong, Allison ^a   Bourke, Michael J ^b   Hayen, Andrew ^a   MacAskill, Petra ^a   Hope, Richard L ^d   Williams, Narelle ^a   Kieu, Anh ^a   Allen, Richard ^e   Chadban, Steven ^e   Pollock, Carol ^f   Webster, Angela ^a,b,c   Roger, Simon D ^g   Craig, Jonathan C ^a,b,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^d BLACKTOWN HOSPITAL   (Australia)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g GOSFORD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL PROTOCOL; COLORECTAL TUMOR; COMORBIDITY; DIAGNOSTIC PROCEDURE; FECES; HUMAN; INTERVIEW; MIDDLE AGED; OCCULT BLOOD; OUTCOME ASSESSMENT; PATIENT PREFERENCE; STANDARD;

ADULT; AGED; CLINICAL PROTOCOLS; COLORECTAL NEOPLASMS; COMORBIDITY; DIAGNOSTIC TECHNIQUES AND PROCEDURES; FECES; HUMANS; INTERVIEWS AS TOPIC; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; OCCULT BLOOD; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT PREFERENCE;

EID: 79959667673     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-11-516     Document Type: Article

References (36)

1. Special data request (2009). Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), 2005
2. The 30th Annual Report. Australian and New Zealand Dialysis and Transplant Registry, 2007
3. Cancer incidencen before and after kidney transplantatio. CM Vajdic, SP McDonald, MR McCredie, et al. JAMA 2006 296 2823 2831 10.1001/jama.296.23.2823 17179459 (Pubitemid 44969182)
4. Cancer inflammation and regulatory T cells. SE Erdman, T Poutahidis, International Journal of Cancer 2010 127 768 779 [Review] [104 refs]
5. Inflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomes. V Filiopoulos, D Vlassopoulos, Inflammation & Allergy Drug Targets 2009 8 369 382 [Review] [118 refs] 21721151
6. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. AC Webster, JC Craig, JM Simpson, MP Jones, JR Chapman, American Journal of Transplantation 2007 7 2140 2151 10.1111/j.1600-6143.2007.01908.x 17640312 (Pubitemid 47247055)
7. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. B Towler, L Irwig, P Glasziou, J Kewenter, D Weller, C Silagy, BMJ 1998 317 559 565 9721111 (Pubitemid 28395924)
8. The UK colorectal cancer screening pilot: results of the second round of screening in England. D Weller, D Coleman, R Robertson, et al. British Journal of Cancer 2007 97 1601 1605 10.1038/sj.bjc.6604089 18026197 (Pubitemid 350249359)
9. Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom. UK Colorectal Cancer Screening Pilot Group, BMJ 2004 329 133 15237087
10. Results from the first three rounds of the Scottish demonstration pilot of FOBT screening for colorectal cancer. RJ Steele, PL McClements, G Libby, et al. Gut 2009 58 530 535 10.1136/gut.2008.162883 19036949
11. Australia's Bowel Cancer Screening Pilot and Beyond. Australian Government of Health and Aging, 2005 FINAL EVALUATION REPORT
12. Australian Government Department of Health and Aging. Australia's Bowel Cancer Screening Pilot and Beyond. Bowel Cancer Screening Pilot Monitoring and Evaluation Steering Committee, 2005 FINAL EVALUATION REPORT
13. Cost-effectiveness of colorectal cancer screening: comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy. BA O'Leary, JK Olynyk, AM Neville, CF Platell, Journal of Gastroenterology & Hepatology 2004 19 38 47 10.1111/j.1440-1746.2004.03177.x 21698355 (Pubitemid 38130605)
14. Cost-effectiveness analysis of screening by faecal occult blood testing for colorectal cancer in Australia. G Salkeld, G Young, L Irwig, M Haas, P Glasziou, Australian & New Zealand Journal of Public Health 1996 20 138 143
15. Costs and cost-effectiveness of full implementation of a biennial faecal occult blood test screening program for bowel cancer in Australia. MP Pignone, KL Flitcroft, K Howard, LJ Trevena, GP Salkeld, DJ St John, Medical Journal of Australia 2011 194 180 185 21401458
16. Screening for colorectal cancer: implications for UK and European initiatives. DP Hurlstone, MA Karajeh, AJ Shorthouse, Techniques in Coloproctology 2004 8 139 145 10.1007/s10151-004-0077-1 15654519 (Pubitemid 40174546)
17. A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test. Z Levi, R Hazazi, P Rozen, A Vilkin, A Waked, Y Niv, Alimentary Pharmacology & Therapeutics 2006 23 1359 1364 10.1111/j.1365-2036.2006.02898.x 21718296
18. Evaluation of combined test of sequential fecal occult blood and albumin in the screening of colorectal neoplasms. S Li, C Zhang, E Xu, Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology] 1995 17 381 383 (Pubitemid 26048610)
19. Reducing mortality from colorectal cancer by screening for fecal occult blood. JS Mandel, JH Bond, TR Church, et al. Minnesota Colon Cancer Control Study New England Journal of Medicine 1993 328 1365 1371 (Pubitemid 23131388)
20. Accuracy of detection of colorectal neoplasia using an immunochemical occult blood test in symptomatic referred patients: comparison of retrospective and prospective studies. H Miyoshi, M Oka, K Sugi, O Saitoh, K Katsu, K Uchida, Internal Medicine 2000 39 701 706 10.2169/internalmedicine.39.701 10969900
21. Recent developments in colorectal cancer screening and prevention. M Pignone, B Levin, American Family Physician 2002 66 297 302 12152966 (Pubitemid 34810082)
22. Cost-effectiveness of colorectal cancer screening in renal transplant recipients. G Wong, K Howard, JC Craig, JR Chapman, Transplantation 2008 85 4 532 41 10.1097/TP.0b013e3181639d35 18347531
23. Low-dose aspirin use and performance of immunochemical fecal occult blood tests. H Brenner, S Tao, U Haug, JAMA 2010 304 2513 2520 10.1001/jama.2010.1773 21139112
24. Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants. Z Levi, P Rozen, R Hazazi, et al. American Journal of Gastroenterology 2009 104 933 938 10.1038/ajg.2009.14 19293792
25. Preventive medical screening is not appropriate for many chronic dialysis patients. JL Holley, Seminars in Dialysis 2000 13 369 371 11130258
26. Life expectancy benefits of cancer screening in the end-stage renal disease population. CJ LeBrun, LF Diehl, KC Abbott, PG Welch, CM Yuan, American Journal of Kidney Diseases 2000 35 237 243 10.1016/S0272-6386(00)70332-5 10676722 (Pubitemid 30070845)
27. Risks and outcomes of peritonitis after flexible colonoscopy in CAPD patients. T Yip, KC Tse, MF Lam, et al. Peritoneal Dialysis International 2007 27 560 564 17704448 (Pubitemid 351176020)
28. Escherichia coli peritonitis after left-sided colonoscopy in a patient on continuous ambulatory peritoneal dialysis. JH Petersen, RE Weesner, RA Giannella, American Journal of Gastroenterology 1987 82 171 172 3101488 (Pubitemid 17015309)
29. Reported cancer screening practices of nephrologists: results from a national survey. G Wong, AC Webster, JR Chapman, JC Craig, Nephrology Dialysis Transplantation 2009 24 2136 2143 10.1093/ndt/gfp009
30. Association of CKD and cancer risk in older people. G Wong, A Hayen, JR Chapman, et al. Journal of the American Society of Nephrology 2009 20 1341 1350 10.1681/ASN.2008090998 19406977
31. Recommendations for the outpatient surveillance of renal transplant recipients. BL Kasiske, MA Vazquez, WE Harmon, et al. American Society of Transplantation Journal of the American Society of Nephrology 2000 11 Suppl-86
32. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.3. Cancer risk after renal transplantation. EBPG Expert Group on Renal Transplantation, Solid organ cancers: prevention and treatment Nephrology Dialysis Transplantation 2002 17 Suppl-6
33. Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. PM Bossuyt, JB Reitsma, DE Bruns, et al. Annals of Internal Medicine 2003 138 40 44 12513043 (Pubitemid 36232093)
34. Cancer mortality in kidney transplantation. BA Kiberd, C Rose, JS Gill, American Journal of Transplantation 2009 9 1868 1875 10.1111/j.1600-6143.2009. 02728.x 19563337
35. Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population. GD Launoy, HJ Bertrand, C Berchi, et al. International Journal of Cancer 2005 115 493 496 10.1002/ijc.20921 (Pubitemid 40663756)
36. Endoscopic mucosal resection outcomes and prediction of submucosal cancer from advanced colonic mucosal neoplasia. A Moss, MJ Bourke, SJ Williams, et al. Gastroenterology 2011